Hepatitis a vaccine immunogenicity and boostability in adults receiving immunosuppressive therapy and adults living with HIV: a prospective single-centre cohort study.

ABSTRACT:

Introduction

Hepatitis A (hepA) vaccination is highly immunogenic in healthy individuals; however, there is uncertainty about the immunogenicity in immunocompromised populations (ICPs).

Methods

In this prospective cohort study, people living with HIV (PLWH), patients on immunosuppressive mono- and combination therapy, and controls received two hepA vaccine doses at months 0 and 6-12, or three combined hepA/B vaccine doses at months 0, 1 and 6-12. Antibody levels were measured before and at different time-points post-vaccination (T2, 6, 8, 12 months). The primary endpoint was the seroconversion rate (SCR) at T8, defined as hepA antibodies ≥20 mIU/ml. To assess boostability, an additional vaccine dose was administered 1-5 years after T12 in those with antibodies < 50 mIU/ml, w

SUBMITTER: Schnyder JL 

PROVIDER: S-EPMC11896842 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature